Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment-Reference-Cited by-同舟云学术

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Published:2021-12 Issue:4 Volume:55 Page:464-478
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sandborn William J.¹,Lawendy Nervin²,Danese Silvio³^ORCID,Su Chinyu²,Loftus Edward V.⁴^ORCID,Hart Ailsa⁵,Dotan Iris⁶⁷,Damião Adérson O. M. C.⁸,Judd Donna T.²,Guo Xiang²,Modesto Irene⁹,Wang Wenjin²,Panés Julian¹⁰

Affiliation:

1. Division of Gastroenterology University of California San Diego La Jolla CA USA

2. Pfizer Inc Collegeville PA USA

3. Gastroenterology and Endoscopy IRCCS Ospedale San Raffaele and University Vita‐Salute San Raffaele Milan Italy

4. Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester MN USA

5. IBD Unit St Mark’s Hospital London UK

6. Division of Gastroenterology Rabin Medical Center Petah Tikva Israel

7. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

8. Department of Gastroenterology University of São Paulo School of Medicine São Paulo Brazil

9. Pfizer Inc New York NY USA

10. Department of Gastroenterology Hospital Clínic de Barcelona IDIBAPS CIBERehd Barcelona Spain

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16712

Reference35 articles.

1. Ulcerative colitis

2. ACG Clinical Guideline: Ulcerative Colitis in Adults

3. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

4. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

5. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis;World Journal of Gastroenterology;2024-09-14

3. Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis;Dermatologica Sinica;2024-09-04

4. A Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease;American Journal of Gastroenterology;2024-06-25

5. Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience;Inflammatory Bowel Diseases;2024-06-03